Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors

Molecular Pharmacology

Volumn 63, Issue 5, 2003, Pages 1032-1042

  Virag, Tamas ^a   Elrod, Don B ^a,d   Liliom, Karoly ^c   Sardar, Vineet M ^b   Parrill, Abby L ^b   Yokoyama, Kazuaki ^a   Durgam, Gangadhar ^a   Deng, Wenlin ^a   Miller, Duane D ^a   Tigyi, Gabor ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b University of Memphis   (United States)

^c INSTITUTE OF ENZYMOLOGY   (Hungary)

^d LYNNTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ALCOHOL; FATTY ALCOHOL PHOSPHATE DERIVATIVE; G PROTEIN COUPLED RECEPTOR; HYDROCARBON; LYSOPHOSPHATIDIC ACID RECEPTOR; MEMBRANE RECEPTOR; PHOSPHATE; RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

AGONIST; ARTICLE; BINDING AFFINITY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG SYNTHESIS; ENERGY; MATHEMATICAL MODEL; PRIORITY JOURNAL; RECEPTOR UPREGULATION; STRUCTURE ACTIVITY RELATION; XENOPUS LAEVIS;

ANIMALS; CELL LINE; HUMANS; OOCYTES; PHOSPHORIC ACID ESTERS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LYSOPHOSPHATIDIC ACID; XENOPUS LAEVIS;

EID: 0038069067     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.5.1032     Document Type: Article

References (39)

1. An S, Bleu T, Zheng Y, and Goetzl EJ (1998) Recombinant human G protein-coupled lysophosphatidic acid receptors mediate intracellular calcium mobilization. Mol Pharmacol 54:881-888.
2. Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, and Inoue K (2000) Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett 478:159-165.
3. Bittman R, Swords B, Liliom K, and Tigyi G (1996) Inhibitors of lipid phosphatidate receptors: N-palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids. J Lipid Res 37:391-398.
4. Carman GM, Deems RA, and Dennis EA (1995) Lipid signaling enzymes and surface dilution kinetics. J Biol Chem 270:18711-18714.
5. Chan CK and Durieux ME (1997) Differential inhibition of lysophosphatidate signaling by volatile anesthetics. Anesthesiology 86:660-669.
6. Cheng HC (2002) The power issue: determination of KB or Ki from IC50. A closer look at the Cheng-Prusoff equation, the Schield plot and related power equations. J Pharmacol Toxicol Methods 46:61-71.
7. Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W, Pyne S, and Tigyi G (2002) International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 54:265-269.
8. Contos JJ, Ishii I, and Chun J (2000) Lysophosphatidic acid receptors. Mol Pharmacol 58:1188-1196.
9. Deng W, Balazs L, Wang D-A, Van Middlesworth L, Tigyi G, and Johnson LR (2002) Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis. Gastroenterology 123:206-216.
10. 2+-independent phosphatidate phosphatase (PAP2) displays diacylglycerol pyrophosphate phosphatase activity. J Biol Chem 272:10361-10366.
11. Fischer DJ, Liliom K, Guo Z, Nusser N, Virag T, Murakami-Murofushi K, Kobayashi S, Erickson JR, Sun G, Miller DD, et al. (1998) Naturally occurring analogs of lysophosphatidic acid elicit different cellular responses through selective activation of multiple receptor subtypes. Mol Pharmacol 54:979-988.
12. Fischer DJ, Nusser N, Virag T, Yokoyama K, Wang D, Baker DL, Bautista D, Parrill AL, and Tigyi G (2001) Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol 60:776-784.
13. Goetzl EJ, Lee H, Dolezalova H, Kalli KR, Conover CA, Hu YL, Azuma T, Stossel TP, Karliner JS, and Jaffe RB (2000) Mechanisms of lysolipid phosphate effects on cellular survival and proliferation. Ann NY Acad Sci 905:177-187.
14. Gueguen G, Gaige B, Grevy JM, Rogalle P, Bellan J, Wilson M, Klaebe A, Pont F, Simon MF, and Chap H (1999) Structure-activity analysis of the effects of lysophosphatidic acid on platelet aggregation. Biochemistry 38:8440-8450.
15. Guo Z, Liliom K, Fischer DJ, Bathurst IC, Tomei LD, Kiefer MC, and Tigyi G (1996) Molecular cloning of a high-affinity receptor for the growth factor-like lipid mediator lysophosphatidic acid from Xenopus oocytes. Proc Natl Acad Sci USA 93:14367-14372.
16. Halgren TA (1996) Merck molecular force field. I. Basis form scope parameterization and performance of MMFF94*. J Comput Chem 17:490-519.
17. Heise CE, Santos WL, Schreihofer AM, Heasley BH, Mukhin YV, Macdonald TL, and Lynch KR (2001) Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol 60:1173-1180.
18. Hooks SB, Ragan SP, Hopper DW, Honemann CW, Durieux ME, Macdonald TL, and Lynch KR (1998) Characterization of a receptor subtype-selective lysophosphatidic acid mimetic. Mol Pharmacol 53:188-194.
19. 2+ mobilization in human A431 cells: Structure-activity analysis. Biochem J 307:609-616.
20. A1/EDG-2 function as lysophosphatidic acid receptors in Xenopus oocytes and mammalian cells. J Biol Chem 276:15208-15215.
21. Liliom K, Bittman R, Swords B, and Tigyi G (1996a) N-Palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids are selective competitive antagonists of the lysophosphatidic acid receptors. Mol Pharmacol 50:616-623.
22. Liliom K, Murakami-Murofushi K, Kobayashi S, Murofushi H, and Tigyi G (1996b) Xenopus oocytes express multiple receptors for LPA-like lipid mediators. Am J Physiol 270:C772-C777.
23. Lynch KR, Hopper DW, Carlisle SJ, Catalano JG, Zhang M, and MacDonald TL (1997) Structure/activity relationships in lysophosphatidic acid: the 2-hydroxyl moiety. Mol Pharmacol 52:75-81.
24. Lynch KR and Macdonald TL (2002) Structure-activity relationships of lysophosphatidic acid analogs. Biochim Biophys Acta 1582:289-294.
25. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, and Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639-1662.
26. Morris GM, Goodsell DS, Huey R, and Olson AJ (1996) Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4. J Comput-Aided Mol Des 10:293-304.
27. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, et al. (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science (Wash DC) 289:739-745.
28. Parrill AL, Wang D, Bautista DL, Van Brocklyn JR, Lorincz Z, Fischer DJ, Baker DL, Liliom K, Spiegel S, and Tigyi G (2000) Identification of Edgl receptor residues that recognize sphingosine 1-phosphate. J Biol Chem 275:39379-39384.
29. Sardar VM, Bautista DL, Fischer DJ, Yokoyama K, Nusser N, Virag T, Wang DA, Baker DL, Tigyi G, and Parrill AL (2002) Molecular basis for lysophosphatidic acid receptor antagonist selectivity. Biochim Biophys Acta 1582:309-317.
30. Siess W, Zangl KJ, Essler M, Bauer M, Brandl R, Corrinth C, Bittman R, Tigyi G and Aepfelbacher M (1999) Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci USA 96:6931-6936.
31. Sugiura T, Tokumura A, Gregory L, Nouchi T, Weintraub ST, and Hanahan DJ (1994) Biochemical characterization of the interaction of lipid phosphoric acids with human platelets: comparison with platelet activating factor. Arch Biochem Biophys 311:358-368.
32. Tigyi G (2001) Physiological responses to lysophosphatidic acid and related glycero-phospholipids. Prostaglandins Other Lipid Mediat 64:47-62.
33. Tigyi G, Liliom K, Fischer DJ, and Guo Z (1999) Phospholipid growth factors: identification and mechanism of action, in Lipid second messengers (Laychock SG and Rubin RP eds) pp 51-81, CRC Press, Boca Raton, FL.
34. Tigyi J, Tigyi G, Liliom K, and Miledi R (1997) Local anesthetics inhibit receptors coupled to phosphoinositide signaling in Xenopus oocytes. Pflueg Arch Eur J Physiol 433:478-487.
35. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, et al. (2002) Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 15:227-233.
36. Van Brocklyn JR, Lee MJ, Menzeleev R, Olivera A, Edsall L, Cuvillier O, Thomas DM, Coopman PJ, Thangada S, Liu CH, et al. (1998) Dual actions of sphingosine-1-phosphate: Extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival. J Cell Biol 142:229-240.
37. Wang DA, Lorincz Z, Bautista DL, Liliom K, Tigyi G, and Parrill AL (2001) A single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors. J Biol Chem 276:49213-49220.
38. Yokoyama K, Baker DL, Virag T, Liliom K, Byun HS, Tigyi G, and Bittman R (2002) Stereochemical properties of lysophosphatidic acid receptor activation and metabolism. Biochim Biophys Acta 1582:295-308.
39. Zhang G, Contos JJ, Weiner JA, Fukushima N, and Chun J (1999) Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate. Gene 227:89-99.